A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 | ResearchBunny

Index

Abstract

This study discovers and characterizes a cross-reactive human IgA monoclonal antibody, MAb362, which binds to both SARS-CoV and SARS-CoV-2 spike proteins and blocks ACE2 receptor binding. MAb362 IgA neutralizes both pseudotyped and authentic SARS-CoV-2 viruses, while the IgG isotype does not. The results suggest that SARS-CoV-2 specific IgA antibodies may provide effective mucosal immunity against SARS-CoV-2.

Publisher

Nature Communications

Published On

Aug 21, 2020

Authors

Monir Ejeme, Qi Li, Shurong Hou, Zachary A. Schiller, Julia A. Tree, Aaron Wallace, Alla Amcheslavsky, Nese Kurt Yilmaz, Karen R. Buttigieg, Michael J. Elmore, Kerry Godwin, Naomi Coombes, Jacqueline R. Toomey, Ryan Schneider, Anudeep S. Ramchetty, Brianna J. Close, Da-Yuan Chen, Hasahn L. Conway, Mohsan Saeed, Chandrashekar Ganesa, Miles W. Carroll, Lisa A. Cavacini, Mark S. Klempner, Celia A. Schiffer, Yang Wang

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants

Y. Du, R. Shi, et al.

Medicine and Health

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

C. Kim, D. Ryu, et al.

Medicine and Health

Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda

D. L. Bugembe, M. V. T. Phan, et al.

Medicine and Health

A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge

Y. Yahalom-ronen, H. Tamir, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny